Posts

7 days in healthcare (January 16th-22nd, 2023)

/in /by

 

Summary

From the point of view of Biomedicine, it is worth highlighting, as the Science article does, the celebration of a decade of CRISPR gene editing technology, whose impact on medicine is only just beginning. Janssen withdraws from the HIV vaccine, a new failure in the attempt to discover a vaccine against this disease. Moderna, on the other hand, presents positive results with a vaccine against bronchiolitis. A new report points to wastewater analysis as fundamental to monitoring threats from a wide variety of diseases, not just covid.

As regards Global Health, The Lancet in an editorial underlines the importance of the One Health concept, this idea of the interdependence between human, animal and ecosystem health. The Economist publishes an editorial and an article on the problems of health systems that are in crisis everywhere in the post-covid era (even in Switzerland!), which is making mortality in Europe have been in the last year 10% higher than in a normal year.

Regarding International Health Policy, in the USA the opponents of abortion are manifested. Problems continue in the NHS, with Sajid Javid, former health secretary, proposing something as unusual in the UK as a co-pay in Primary Care and Emergency. He says an overly religious view of the NHS prevents reforms. Important debate and tensions about the price of medicines in the European continent (UK and EU) in relation to prices in the USA. Pharmaceutical companies, very reluctant to price controls, when they are also in the USA with the application of the Inflation Act, which gradually imposes a negotiation of the price of medicines between the Medicare Administration and pharmaceutical companies.

If we talk about National Health Policy (Spain), the incidence of covid continues to drop. Medical conflicts extend to various autonomous communities (Madrid, Catalonia, Navarra, etc.). The agreement in Aragon should be highlighted, which indicates that it is possible to reach agreements, possibly when they are well negotiated. The Ministry, completely absent from this problem. As for the public system, the statements by Lasquetty, Madrid’s Treasury Councilor, who points to “my own place” as one of the great rigidities of the public system, are very interesting. Conflict also in private health between doctors and insurers, raised in Seville. Abortion enters the national debate, following the picturesque proposals of Vox in Castilla y León, never applied. The Constitutional Court opens its new session with the debate on the recourse to the Law of deadlines presented in its day by the PP. The CIS survey presents health as the second problem that worries the Spanish.

In the field of Companies, internationally, Pfizer’s initiative to sell medicines at cost prices in 45 poor countries must be highlighted. At the national level, the launch by DKV of an insurance product that allows choosing a family doctor is notable. In a context in which insurers actually forget about Primary Care, this is something that deserves to be highlighted.

Biomedicine

Global Health

International Health Policy

National Health Policy

Companies

7 days in healthcare (November 21st-27th, 2022)

/in /by

 

Summary

Most notably from the Biomedicine standpoint, the FDA is approving a drug that could delay the onset of type 1 diabetes, the devastating disease that often occurs in adolescents. Also the preclinical study that seems to foreshadow a universal flu vaccine. Likewise, the minirobot designed by Apple capable of taking medicines to the brain, that organ until now practically inaccessible to drugs.

With regard to Global Health, the COP27 summit is considered in an article in The Lancet a “collective failure”, given the lack of agreement on the lower use of fossil fuels. We must also note the race for the production of vaccines in several African countries.

Regarding International Health Policy, mortality from covid remains high and is very worrying in some countries, mainly Japan, Brazil, India, China, the Russian Federation, South Korea and Spain. The covid-zero policy is generating problems and discontent in a country where public demonstrations are as controlled as in China. The nurses’ strike in the United Kingdom is a historic event in that country, which will undoubtedly will have consequences.

If we talk about National Health Policy (Spain), mortality from covid remains high in Spain (260 cases in the last week). At this time Spain has 0.6 deaths per 100,000 inhabitants, a fairly high mortality, although lower than other European countries, such as France, Greece, Denmark, Norway, Croatia, Estonia and Luxembourg, according to WHO data. The waiting lists for June 30 are published by the Ministry of Health. A real national problem and a serious delegitimization of the public system, which some minimize. The strike of Primary Care doctors continues in Madrid, while the conflict threatens to spread to other autonomous communities. The rise in the electricity bill threatens the profitability of private hospitals, according to ASPE.

In the field of Companies, at the international level, Amazon is making a new foray into healthcare, this time with the “Amazon Clinic” platform, a telemedicine service that will be extended to 32 American states and offers virtual care for 20 clinical conditions. At the national level, news at HM Hospitales, with the new hospital in Rivas; in Recoletas, which extends to Salamanca; and, in Sanitas, which intends to create its own clinical analysis laboratory.

Biomedicine

Global Health

International Health Policy

National health policy

Companies

  • International News
    • Amazon makes a new attempt at healthcare. The offers of the big technological platforms are diversified: Apple tries to monitor through the iPhone; Microsoft, offers computer services to companies; Alphabet (Google), relies on wearables. Amazon launches the most ambitious offer, with “Amazon Clinic”, an online service that will operate in 32 American states and that offers virtual care for 20 clinical conditions, from acne to allergies (https://www.economist.com/ business/2022/11/20/amazon-makes-a-new-push-into-health-care)
    • The big pharma aims for 50,000 million dollars in medicines against obesity, a disease that affects 650 million people in the world, as demand grows. Lilly will submit a drug for authorization (https://www.ft.com/content/f28e8ca1-87a7-4c14-8b05-0ead0e831c0f)